LA JOLLA, CA, May 22, 2023 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today provided a business outlook and highlighted upcoming…Read More
GRI Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators
